Abstract
The number of MDR TB cases continues to increase. Various new drugs are being developed to provide effective therapy in handling TB. In-depth understanding is required by clinicians to monitor the progress of therapy for MDR TB. This article aims to explain the pathophysiology of resistance in TB and the pharmacological aspects of the latest antituberculosis drugs in MDR TB.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
